Media Thread, page-15633

Nice, well-balanced article here ... thanks for posting @col69

This is a good, simple read for those looking to get their head around the latest Azer-cel results from IMU.

The focus is of course on Cohort B where a small dose of IL2 has been added.

This cohort currently has a Complete Response Rate (CR) of 67%. And its durable!

You can make up your own mind if you think this good. The word I would choose is ‘stunning’.

If either of the more recently dosed patients gain a response then we could be looking at something really special here.

The article clearly explains why IL2 has been introduced, and in an answer to one of my questions to Leslie, she explained that it was actually a tiny dose, certainly smaller than I thought might be applied. The power of IL2 to help T-Cells not only survive, but grow, is well documented.

The safety read out is also excellent ... no high Cytokine Release Syndrome and no evidence of GvHD, as hoped, particularly as we are using an allogeneic therapy. GvHD is a huge challenge and a very big issue. As an added bonus, no ICANS observed so I would expect that the FDA will love this safety profile.

It looks like IMU are now satisfied with the dosing level so it’s ‘all systems go’.

The article notes that it is only a small sample, which it certainly is ... but it couldn’t be much better.

In my view, we are looking at IMU’s first commercial product ... especially if the ‘next’ data cut reflect the current results. Fingers and toes crossed.

All opinion, of course.